Table 3.
Studies using three‐fraction SBRT for spinal metastases
| Reference | Patients (Lesions) | Age (median) | Sex (male/female) | Tumor type | Dose (Gy, median) | Follow‐up (mo, median) | Local control (1‐y) | Overall survival (1‐y) | MINORS |
|---|---|---|---|---|---|---|---|---|---|
| Folkert et al14 | NA (52) | NA | NA | Mixed | 28.5 | 12.3 | 84.1% | 46.2% | 20 |
| Wang et al37 | 149 (166) | 58 | 77/72 | Mixed | 27‐30 | 15.9 | 80.5%a | 71.9% | 15 |
| Silva et al38 | NA (20) | NA | NA | Mixed | 27 | 13.58 | 87.8% | NA | 12 |
| Ghia et al15 | NA (26) | NA | NA | RCC | 27 | 23 (overall) | 71% | NA | 22 |
| Park et al39 | 39 (59) | 61 | 24/15 | Mixed | 27 | 7.4 | 93.2% | 47.4% | 12 |
| Garg et al40 | 59 (63) | 60 | 35/24 | Mixed | 27 | 17.6 (mean) | 76% | 76% | 14 |
| Laufer et al20 | 37 (NA) | NA | NA | Mixed | 27 | 7.6 | 95.9% | NA | 12 |
| Mehta et al41 | 83 (98) | 64 | 47/36 | Mixed | 24 | 7.6 | 84% | 46% | 12 |
| Anand et al42 | 52 (76) | 58 | 30/22 | Mixed | 24 | 8.48 | 94% | 68% | 12 |
| Guckenberger et al43 | 301 (387) | 61.3 | 166/135 | Mixed | 24 | 11.8 | 89.9% | 64.9% | 12 |
| Kim et al44 | 22 (31) | 56 | 9/13 | Mixed | 24 | 10 | 81.3% (6‐mo)a | 64.5% (6‐mo) | 11 |
| Ahmed et al45 | 66 (85) | 56.8 | 48/18 | Mixed | 24 | 8.2 | 89.2% | 52.2% | 12 |
| Sahgal et al46 | 39 (60) | NA | NA | Mixed | 24 | 9 and 7b | 85% | 45% (2‐y) | 20 |
| Puvanesarajah et al47 | 99 (NA) | 60.4 | 51/48 | Mixed | 21 | 6.1 | NA | 43.7% | 12 |
Abbreviations: Gy, gray; mo, month; NA, not applied; RCC, renal cell carcinoma; y, year.
a
Tumor progression‐free survival rates.
b
Median follow‐up for unirradiated and reirradiated group, respectively.